PL
Paul F. Lizzul
Chief Medical Officer

Paul F. Lizzul insider trades: Anaptysbio (ANAB) stock buys and sales

Chief Medical Officer, Anaptysbio Last trade Jan 7, 2026 30 Form 4 filings
$358K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2017
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Paul reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 7, 2026ANAB↓ Sell$101K
Jan 5, 2026ANAB↓ Sell$183K
Dec 22, 2025ANAB↓ Sell$75K
Sep 23, 2024ANAB↓ Sell$58K
Sep 16, 2024ANAB↓ Sell$86K
Aug 14, 2024ANAB↓ Sell$80K
Jul 18, 2024ANAB↓ Sell$53K
Jan 8, 2024ANAB↓ Sell$56K
Sep 14, 2023ANAB↓ Sell$41K
Aug 1, 2017SNNA↑ Buy$150K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ANAB insiders

Open-market trades in the last 12 months

About Paul F. Lizzul's insider trades

Paul F. Lizzul is Chief Medical Officer at Anaptysbio (ANAB). Since Aug 1, 2017, Paul has reported 1 open-market purchase worth $150K and 9 sales worth $732K on SEC Form 4. In the last 12 months: 3 sales ($358K).

Their filings also include grants and awards (20 filings), option exercises (10 filings), shares withheld for taxes (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ANAB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.